Every Form 4 that Anavex Life Sciences (AVXL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVXL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVXL filings page.
ANAVEX LIFE SCIENCES CORP. reported that Sandra Boenisch, PFO & Treasurer, had four previously granted stock-option awards become immediately vested and exercisable on September 24, 2026. The options cover 20,000 shares at a $10.09 exercise price, 25,000 at $8.57, 25,000 at $5.36 and 25,000 at $8.58. The vesting followed the board election at the 2026 Annual Meeting, which the company described as a “change in control” under its incentive plans and her employment agreement.
Anavex Life Sciences reported that President and CEO Christopher Missling had 125,000 stock options vest on January 6, 2026. These options have an exercise price of $8.58 per share and are shown as acquired at a price of $0, reflecting the vesting of an existing award rather than a market purchase. The options are part of a larger grant made on March 31, 2025 covering 500,000 shares, structured to vest in four equal performance-based tranches.
One milestone for this grant was achieving a Second Regulatory dialogue for blarcamesine. The filing states that the performance criteria for this milestone were met, causing this 125,000-share tranche to vest. Following the transaction, Missling directly holds 125,000 derivative securities (stock options), each representing one share of common stock, with an expiration date of March 31, 2035.
Anavex Life Sciences Corp. reported that its PFO & Treasurer, Sandra Boenisch, acquired a derivative security in the form of a stock option on January 6, 2026. The option covers 12,500 shares of common stock at an exercise price of $8.58 per share and is exercisable until March 31, 2035.
The 12,500-share tranche comes from an earlier option grant dated March 31, 2025 for 50,000 shares that vests in four equal performance-based tranches. One milestone was achieving a second regulatory dialogue for blarcamesine, and meeting this performance criterion triggered vesting of this 12,500-share portion, which Boenisch now holds directly.